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We read with interest the article by Bress
et al. (1) reporting on the effect of inten-
sive versus standard blood pressure treat-
ment according to baseline prediabetes
status in a post hoc analysis of the Sys-
tolic Blood Pressure Intervention Trial
(SPRINT). The authors concluded that
the beneﬁcial effects of intensive blood
pressure treatment were similar among
patients with prediabetes and patients
with normoglycemia. We have partici-
pated in the SPRINT Data Analysis Chal-
lenge (2), andwe also analyzed the effects
of glycemia status in this population.
Whereas we agree with the conclusions
presented by the authors, we believe it is
also important to assess the effect of pre-
diabetes on cardiovascular events and
death in patients at high risk for cardio-
vascular events.
Previous studies have reported an in-
crease incardiovascular riskamongpatients
with prediabetes (3–5). However, most of
these trials have evaluated patients at low
or moderate cardiovascular risk (3–5).
Using the SPRINT challenge data set,
we evaluated the occurrence of the pri-
mary outcome (composite of myocardial
infarction, acute coronary syndrome not
resulting in myocardial infarction, stroke,
acute decompensated heart failure, or
death from cardiovascular causes) and
the SPRINT secondary outcomes among
patients with prediabetes compared
with patients with normoglycemia. We
used Cox proportional hazards regression
models to test for an association between
prediabetes and each outcome. We also
tested this association adjusting for age,
sex, baseline systolic blood pressure,
smoking, chronic kidney disease, cardio-
vascular disease at baseline, black race,
BMI, statins and aspirin use, and treat-
ment arm. The unadjusted hazard ratio
for the primary outcome was 1.08 (95%
CI 0.91, 1.28; P = 0.390) in patients with
prediabetes compared with patients with
normoglycemia. The adjusted hazard
ratio for the primary outcome was 1.05
(0.88, 1.25; P = 0.560) in patients with
prediabetes compared with patients
with normoglycemia. We also found no
signiﬁcant differences regarding the pre-
speciﬁed secondary outcomes of SPRINT.
Webelieve our results are important as
they suggest that prediabetes status may
not increase cardiovascular risk among pa-
tients athigh risk for cardiovascular events,
in contrast with what has been described
in patients with low cardiovascular risk.
Note that, as in the article by Bress
et al. (1), this analysis was not prespeci-
ﬁed and that SPRINT was not designed to
answer this question. We cannot exclude
that the risk of patients with prediabetes
might have been higher if the follow-up
had been longer or if prediabetes status
had been deﬁned by HbA1c levels and/or
oral glucose tolerance tests.
In summary, the results fromSPRINTnot
only highlight that intensive blood
pressure is beneﬁcial in both patients
with prediabetes and patients with nor-
moglycemia but also suggest that predi-
abetes does not further increase
cardiovascular risk among patients at
high risk for cardiovascular events.
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